mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]
The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019, in recognition of their industrial activity and their commitment to development and innovation. After four consecutive years of obtaining the “Very Good” rating, this plan, an initiative of the Ministry of Industry, […]
The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children. A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long-standing gap in the treatment of congenital infections of Chagas disease. The donation, by the Mundo Sano Foundation1 and […]
The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Garín, Buenos Aires (Argentina). These drugs are used in the treatment of oncological and autoimmune diseases such as rheumatoid arthritis. With this new plant, the company now has three biosimilar plants, two in Argentina and one in […]
Meet us at BIO-Europe, to be held 23 – 25 March in Paris, France Meet us at CPHI, to be held 13-15 October in Milan, Italia
Meet us at CPhl, to be held 5-7 November in Frankfurt, Germany. Meet us at BIO-EUROPE, to be held 11-13 November in Hamburg, Germany.